Blood tests could transform cancer screening soon : NPR

Key Points:

• The FDA is evaluating the Galleri blood test, which can detect up to 50 types of cancer from a single blood sample, with potential approval later this year that could revolutionize cancer screening by making it more comprehensive and accessible.
• Currently, U.S. cancer screening focuses on five cancers with separate tests, but Galleri and similar tests like Cancerguard offer multi-cancer early detection (MCED), pending full FDA approval and insurance coverage, including Medicare reimbursement starting in 2028.
• Large-scale studies of Galleri show promising results, including a 26% reduction in Stage IV cancers in the third year, although it is intended to complement existing screening tests rather than replace them.
• Experts highlight that blood-based cancer tests could simplify routine screening and improve early detection, while ongoing advancements in liquid biopsy technology are already enhancing cancer treatment monitoring and personalization.
• While Galleri is not diagnostic, it helps predict cancer origin to guide follow-up exams, and combined with advances in treatment, these blood tests have the potential to improve cancer survival and outcomes significantly.